This content is only available within our institutional offering.
12 Sep 2019
ROCHE: Two more clinical successes announced | BUY - Top Picks | CHF340(+25%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE: Two more clinical successes announced | BUY - Top Picks | CHF340(+25%)
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
12 Sep 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
ROCHE - BUY - Top Picks | CHF340(+25%)
Two more clinical successes announced
Two positive trial read-outs are made this morning
Tecentriq works in monotherapy in 1L PD-L1 high NSCLC patients
Satralizumab is now ready to be filed
A PharmaDay next Monday to be held in London